Brief: Heidelberg Pharma H1 2022 Sales Revenue At EUR 11.9 Mln

Heidelberg Pharma AG

12/07/2022 06:14

July 12 (Reuters) - Heidelberg Pharma AG  HPHA.DE :
    * IN FIRST SIX MONTHS OF 2022 FISCAL YEAR, HEIDELBERG PHARMA
GROUP
GENERATED SALES REVENUE AND INCOME TOTALING EUR 12.2 MILLION,
THUS SIGNIFICANTLY INCREASING PREVIOUS YEAR'S TOTAL (EUR 1.1
MILLION) AS A RESULT OF PARTNERSHIP WITH HUADONG
    * SALES REVENUE TOTALING EUR 11.9 MILLION COMPRISES
GROUP-WIDE
COLLABORATION AGREEMENTS FOR ATAC® TECHNOLOGY (EUR 11.6 MILLION)
AND SERVICE BUSINESS OF HEIDELBERG PHARMA RESEARCH (EUR 0.3
MILLION)
    * OPERATING EXPENSES, INCLUDING DEPRECIATION, AMORTIZATION
AND
IMPAIRMENT, AMOUNTED TO EUR 18.5 MILLION IN REPORTING PERIOD
(PREVIOUS YEAR: EUR 14.0 MILLION)
    * NET LOSS POSTED BY HEIDELBERG PHARMA GROUP FOR FIRST SIX
MONTHS
OF 2022 CAME TO EUR 8.6 MILLION (PREVIOUS YEAR: EUR 13.1
MILLION)
    * EARNINGS PER SHARE AMOUNTED TO EUR - 0.25 AND, TAKING INTO
ACCOUNT HIGHER NUMBER OF SHARES, DEVELOPED POSITIVELY COMPARED
WITH PREVIOUS YEAR (EUR -0.42).
    * ALTHOUGH ALL NECESSARY APPROVALS FOR TRANSACTION HAVE BEEN
GRANTED IN MEANTIME, FINANCIAL OUTLOOK IS STILL SUBJECT TO
CONDITION PRECEDENT OF A SUCCESSFUL CAPITAL INCREASE, WHICH IS
PLANNED FOR END OF AUGUST/BEGINNING OF SEPTEMBER
    * IN THIS RESPECT, FULL-YEAR FINANCIAL GUIDANCE ISSUED ON 24
MARCH
2022 FOR HEIDELBERG PHARMA GROUP WILL NOT BE ADJUSTED AT THIS
TIME

Source text for Eikon:  ID:nEQ8ZQc1xa 
Further company coverage:  HPHA.DE 

 ((frankfurt.newsroom@thomsonreuters.com;))